PLEASE NOTE: Specialty Compounding PHARMACY IS NOT LICENSED TO DISTRIBUTE IN NORTH CAROLINA.
To date, no cases have been identified outside of Texas. However, it is possible that patients who were exposed to this product could travel to other states before presenting for care.
The FDA requests that health care professionals report any adverse reactions that might be related to use of these products to FDA’s MedWatch program either by completing and submitting the report online here or downloading and completing the form, then submitting it via fax at 1-800-FDA-0178.
For more information, please visit this site.